Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2018: The unmet needs in maintenance therapy for multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 15.06.18
Views: 1680

Prof Meletios Dimopoulos, Dr Shaji Kumar, Prof Meral Beksaç and Prof Wee Joo Chng

Dr Meletios Dimopoulos, Professor Meral Beksac, Professor Wee Joo Chng and Dr Shaji Kumar discuss the unmet needs in maintenance therapy for patients with multiple myeloma at the 23rd EHA congress.

The conversation opens with a discussion around a number of potential maintenance therapies in newly diagnosed multiple myeloma, including: thalidomide, bortezomib and lenalidomide with the panel talking around the associated benefits and also risks of these therapeutic options.

The panel discuss the subsets of patients who do not benefit from maintenance therapy, in particular those with high risk disease and those with renal impairment.

The debate between continuous versus fixed duration therapy is discussed with the panel sharing the opinion that analysis of minimal residual disease and depth of response will have potential use in the future to guide clinical decisions around duration of therapy.

The panel discuss current ongoing trials clinical trials in this setting, in particular trials investigating oral ixazomib as a potential long-term therapy in patients with multiple myeloma.

Maintenance therapies for MM
Depth of response with -imid therapy
Prospects for bortezomib maintenance
Recommendations for lenalidomide maintenance
Management of high risk disease
Duration of therapy
Clinical trials in MM
Combination therapies in disease management
Impact of 17P deletion on treatment options

This programme has been supported by an unrestricted educational grant from Takeda

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation